Weight-loss drug Wegovy shows promise for heart failure patients

Clinical trials indicate Wegovy reduces symptoms and improves quality of life in heart failure patients with obesity.
Wegovy led to significant improvements in exercise capacity and physical limitations compared to placebo.
Patients taking Wegovy lost over 13% of body weight on average versus 2.6% for placebo group.
Studies suggest Wegovy decreases risk of cardiovascular events like stroke and heart attack.
Experts say more research is needed on long-term cardiovascular benefits and potential for reduced hospitalizations.